Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Y-6 Sublingual Tablets in Acute Ischemic Stroke Post-Endovascular Therapy
ChiCTR2500105795Phase 3Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Y-6 sublingual tablet group with Placebo group (2 arms). Primary endpoint: Proportion of patients with mRS 0–1 at day 90. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
cilostazol + dexborneol
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2500105795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105795.